The purpose of this Phase 3 study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
To Learn More Contact
BMS Study Connect Contact Center www.BMSStudyConnect.com or call 855-907-3286 or email Clinical.Trials@bms.com. First line of the email must contain the NCT number and the number of the trial site.
ClinicalTrials.gov identifier (NCT number): NCT05617677